Navigation Links
New Hepatitis C Drug Close to Gaining FDA Approval
Date:4/28/2011

THURSDAY, April 28 (HealthDay News) -- Boceprevir, a new medication from Merck & Co. that changes the way hepatitis C is treated, won unanimous support Wednesday from a panel of experts convened by the U.S. Food and Drug Administration.

The drug is one of two new medications against hepatitis C that are up for agency approval. Many experts believe that, if approved, boceprevir and the second medicine, telaprevir, could revolutionize treatment of hepatitis C-linked disease.

The U.S. Centers for Disease Control and Prevention estimated 17,000 new hepatitis C virus infections in the United States in 2007. Many people with the disease have no symptoms until it has caused liver damage, sometimes so severe that a liver transplant is needed.

Studies found that when used with two older drugs, boceprevir reduced levels of the virus more effectively than the existing treatments. Merck, headquartered in Whitehouse Station, N.J., hopes to sell the medication under the brand name Victrelis, according to Dow Jones.

Telaprevir, a similar drug made by Vertex Pharmaceuticals of Cambridge, Mass., is scheduled for review Thursday by the same panel of non-FDA experts.

Debra Birnkrant, director of FDA's antiviral-drugs division, said that both medications appear to increase the cure rate "to more than 30 percent above what we have today," Dow Jones reported.

The new drugs take treatment of hepatitis C in a new direction. Both boceprevir and telaprevir block protease, an enzyme that helps the virus reproduce. The earlier drugs, pegylated interferon and ribavirin, were meant to boost the immune system's defense against the virus. Together, the combined medications may offer new hope for the thousands of Americans with the contagious liver disease.

Asked if the available data supported use of boceprevir in combination with standard treatment of pegylated interferon and ribavirin, the panel of medical experts voted 18-0 in favor, Dow Jones reported. This is considered a recommendation to approve the drug.

Although FDA does not have to follow the panel's advice, it usually does.

One of the boceprevir studies found it effective for 66 percent of patients taking the three-drug regimen compared to 38 percent of those who received the standard two-drug treatment, Dow Jones said.

Some concerns still need to be addressed, including how to treat black patients, for whom the drugs seem to be less effective.

Studies submitted by the manufacturers showed the new drugs, when added to existing treatments, shortened the length of medication therapy, thereby reducing potential side effects. Patients currently require nearly 12 months of treatment.

Telaprevir's cure rates appear to be better than boceprevir's, the Associated Press reported.

Until the early 1990s, when testing of the nation's blood supply became routine, hepatitis C was often contracted from blood transfusions. Today it is most commonly associated with injection drug use. It is also transmitted through sexual contact with an infected person, the CDC said.

Earlier this year, a study from the Johns Hopkins School of Public Health called for greater efforts to reduce the population of hepatitis C-infected injection drug users. That study found that new cases of hepatitis C were decreasing only among younger injection drug users who had recently starting using the drugs.

More information

To learn more about hepatitis C, visit the U.S. National Library of Medicine.

-- HealthDay staff

SOURCES: U.S. Centers for Disease Control and Prevention; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New screening system for hepatitis C
2. Groundbreaking research to find vaccine for hepatitis C
3. 1 in 5 At-Risk U.S. Babies Doesnt Get Hepatitis B Vaccine
4. Vaccination, Prevention Is Beating Back Hepatitis
5. Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis
6. Hepatitis C treatment less effective in urban minority patients
7. Researchers identify potential new target for treating hepatitis C
8. Donor kidneys from Hepatitis C patients needlessly denied to patients with that infection
9. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
10. New Drug Shows Promise for Curing Hepatitis C
11. Hepatitis C Tied to Higher Kidney Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... ... “Letters From Home”: a moving compilation of letters that remind readers of ... Home” is the creation of published author, John Allred, a passionate leader of ministry ... International, who has traveled and ministered on four continents. , “It is my hope ...
(Date:9/21/2017)... CA (PRWEB) , ... September 21, 2017 , ... With ... so fun and easy to do. Users can select from up to two layers ... with a click of a mouse all within Final Cut Pro X. ...
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction Treatment ... for professionals in the addiction treatment industry entitled: Special Investigations Unit (SIU) ... companies and state and federal governments are increasingly scrutinizing the addiction treatment industry ...
(Date:9/21/2017)... ... ... Bill Howe Plumbing’s mission is to create an employee friendly company, provide ... over 37 years, they have operated with their mission at the foundation and have ... They were chosen as the Best San Diego plumber in 2016, named a Top ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... developing low-cost and highly accurate cancer screening tests, has received two prestigious recognitions ... in cancer survival rates. , Preora has been named a Top ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and ... primary and secondary endpoint data for lasmiditan, an investigational, ... which demonstrated statistically significant improvements compared to placebo in ... highlighted today at the 18th Congress of the International ... "The data presented today demonstrate lasmiditan,s potential ...
(Date:9/7/2017)... WARSAW, Ind. , Sept. 7, 2017  Zimmer ... leader in musculoskeletal healthcare, today announced that it will ... Annual Global Healthcare Conference at the Grand Hyatt hotel ... September 11, 2017 at 11:40 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
Breaking Medicine Technology: